Rapid and regular dose escalation in urate lowering therapy: a pragmatic clinical trial.
Clin RheumatolJul 28, 2026 (epub)
Bingqing Zhang, Yingdong Han, Yue Yin et al.
✦ AI-curated · Sources linked
In 30 seconds
This pragmatic clinical trial evaluated rapid versus regular dose escalation strategies for urate-lowering therapy in 172 gout patients. The rapid group had a higher post-escalation flare rate (37.9% vs 23.5%, P=0.041) but achieved serum uric acid targets faster (median 4.93 vs 6.43 months, P=0.020).
Key findings
- Post-escalation flare rate was higher in the rapid group at 37.9% compared to 23.5% in the regular group.
- Serum uric acid target achievement rates were similar: 60.9% for rapid vs 62.4% for regular escalation.
- The rapid group achieved target serum uric acid levels significantly faster, with a median of 4.93 months.
- The rapid group had a higher likelihood of target attainment with an adjusted hazard ratio of 1.55.
Why it matters
Understanding the risks and benefits of different dose escalation strategies for urate-lowering therapy can help clinicians tailor treatment plans for gout patients, balancing the need for rapid symptom control with the potential for increased flare rates.